[go: up one dir, main page]

EP3347012A4 - Combinaisons muscariniques et leur utilisation pour lutter contre des troubles hypocholinergiques du système nerveux central - Google Patents

Combinaisons muscariniques et leur utilisation pour lutter contre des troubles hypocholinergiques du système nerveux central Download PDF

Info

Publication number
EP3347012A4
EP3347012A4 EP16845102.9A EP16845102A EP3347012A4 EP 3347012 A4 EP3347012 A4 EP 3347012A4 EP 16845102 A EP16845102 A EP 16845102A EP 3347012 A4 EP3347012 A4 EP 3347012A4
Authority
EP
European Patent Office
Prior art keywords
muscarinic
combinations
controlling
nervous system
central nervous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16845102.9A
Other languages
German (de)
English (en)
Other versions
EP3347012A1 (fr
Inventor
Thomas N. Chase
Kathleen E. Clarence-Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chase Pharmaceuticals Corp
Original Assignee
Chase Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chase Pharmaceuticals Corp filed Critical Chase Pharmaceuticals Corp
Publication of EP3347012A1 publication Critical patent/EP3347012A1/fr
Publication of EP3347012A4 publication Critical patent/EP3347012A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP16845102.9A 2015-09-11 2016-09-09 Combinaisons muscariniques et leur utilisation pour lutter contre des troubles hypocholinergiques du système nerveux central Withdrawn EP3347012A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562217081P 2015-09-11 2015-09-11
US201662351382P 2016-06-17 2016-06-17
PCT/US2016/050907 WO2017044714A1 (fr) 2015-09-11 2016-09-09 Combinaisons muscariniques et leur utilisation pour lutter contre des troubles hypocholinergiques du système nerveux central

Publications (2)

Publication Number Publication Date
EP3347012A1 EP3347012A1 (fr) 2018-07-18
EP3347012A4 true EP3347012A4 (fr) 2019-04-17

Family

ID=58240063

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16845102.9A Withdrawn EP3347012A4 (fr) 2015-09-11 2016-09-09 Combinaisons muscariniques et leur utilisation pour lutter contre des troubles hypocholinergiques du système nerveux central

Country Status (3)

Country Link
EP (1) EP3347012A4 (fr)
CA (1) CA2996719A1 (fr)
WO (1) WO2017044714A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
PL3061821T3 (pl) 2009-07-22 2020-01-31 PureTech Health LLC Kompozycje do leczenia zaburzeń łagodzonych przez aktywację receptora muskarynowego
JP7096441B2 (ja) 2018-09-28 2022-07-05 カルナ セラピューティックス,インコーポレイテッド ムスカリン受容体活性化によって改善される障害を処置するための組成物及び方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016144719A1 (fr) * 2015-03-06 2016-09-15 Chase Thomas N Combinaison d'agoniste des récepteurs muscariniques et d'oxybutynine dans un système thérapeutique transdermique
WO2016144749A1 (fr) * 2015-03-06 2016-09-15 Chase Thomas N Système thérapeutique transdermique constitué de combinaisons d'oxybutynine et de xanoméline
WO2017015349A1 (fr) * 2015-07-20 2017-01-26 Chase Pharmaceuticals Corporation Combinaison muscarinique d'un antagoniste sélectif du récepteur m2 et d'un antagoniste non sélectif périphérique pour le traitement de troubles hypocholinergiques
WO2017044693A1 (fr) * 2015-09-11 2017-03-16 Chase Pharmaceuticals Corporation Combinaison muscarinique et son utilisation pour lutter contre des troubles hypocholinergiques du système nerveux central
WO2017147104A1 (fr) * 2016-02-24 2017-08-31 Chase Pharmaceuticals Corporation Combinaisons d'antagoniste muscarinique m2

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030124176A1 (en) * 1999-12-16 2003-07-03 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
US20130289019A1 (en) * 2012-04-26 2013-10-31 Amazing Grace, Inc. Methods of treating behaviorial and/or mental disorders
WO2014039627A1 (fr) * 2012-09-05 2014-03-13 Chase Pharmaceuticals Corporation Composition et procédés neuroprotecteurs anticholinergiques

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016144719A1 (fr) * 2015-03-06 2016-09-15 Chase Thomas N Combinaison d'agoniste des récepteurs muscariniques et d'oxybutynine dans un système thérapeutique transdermique
WO2016144749A1 (fr) * 2015-03-06 2016-09-15 Chase Thomas N Système thérapeutique transdermique constitué de combinaisons d'oxybutynine et de xanoméline
WO2017015349A1 (fr) * 2015-07-20 2017-01-26 Chase Pharmaceuticals Corporation Combinaison muscarinique d'un antagoniste sélectif du récepteur m2 et d'un antagoniste non sélectif périphérique pour le traitement de troubles hypocholinergiques
WO2017044693A1 (fr) * 2015-09-11 2017-03-16 Chase Pharmaceuticals Corporation Combinaison muscarinique et son utilisation pour lutter contre des troubles hypocholinergiques du système nerveux central
WO2017147104A1 (fr) * 2016-02-24 2017-08-31 Chase Pharmaceuticals Corporation Combinaisons d'antagoniste muscarinique m2

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2017044714A1 *
SRAMEK J J ET AL: "THE SAFETY AND TOLERANCE OF XANOMELINE TARTRATE IN PATIENTS WITH ALZHEIMER'S DISEASE", JOURNAL OF CLINICAL PHARMACOLOGY, LIPPINCOTT CO, HAGERSTOWN, MD, US, vol. 35, 1 January 1995 (1995-01-01), pages 800 - 806, XP000563129, ISSN: 0091-2700 *

Also Published As

Publication number Publication date
WO2017044714A1 (fr) 2017-03-16
EP3347012A1 (fr) 2018-07-18
CA2996719A1 (fr) 2017-03-16

Similar Documents

Publication Publication Date Title
EP3692158A4 (fr) Thérapies géniques pour troubles lysosomiaux
EP3692075A4 (fr) Thérapies géniques pour troubles lysosomaux
EP3364993A4 (fr) Procédés pour traiter le syndrome d'angelman et des troubles associés
EP3692151A4 (fr) Thérapies géniques pour troubles lysosomaux
EP3104708A4 (fr) Thérapie cellulaire régénérative pour troubles du système nerveux central (snc) et espt
HRP20210518T1 (hr) Derivati 2,4-tiazolidindiona, namijenjeni liječenju poremećaja središnjeg živčanog sustava
ZA201806382B (en) Liquid filter arrangement and methods
MA51075A (fr) Procédés et compositions pour traiter des troubles à l'aide de polypeptides de follistatine
EP2807412A4 (fr) Procédés et systèmes de surveillance nerveuse pour le traitement de troubles pharyngés
DE112015004742A5 (de) Separatorplatte und elektrochemisches System
SG11201607705XA (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
HUE051488T2 (hu) Készítmények és eljárások központi idegrendszeri rendellenességek kezelésére
EP3243663A4 (fr) Tête de déversement de liquide, unité de déversement de liquide, et dispositif pour déverser un liquide
HUE054092T2 (hu) Központi idegrendszeri zavarok kezelésére szolgáló kompozíciók és eljárások
PL3392931T3 (pl) Separator dla urządzenia elektrochemicznego i urządzenie elektrochemiczne go zawierające
EP3235470A4 (fr) Biohybride à utiliser dans la régénération de fibres neuronales
EP3442547A4 (fr) Thérapies à base de probiotiques pour troubles du développement et autres troubles neurologiques
EP3151205A4 (fr) Machine tout-en-un à circulation et dispositif de distribution de billets de banque de celle-ci
EP3618824A4 (fr) Utilisation de n-acétylcystéine pour traiter des troubles du système nerveux central
SG11201608397UA (en) Glyt1 inhibitors for use in the treatment of hematological disorders
HUE057479T2 (hu) Szûrõkészülék elválasztólappal
EP3347012A4 (fr) Combinaisons muscariniques et leur utilisation pour lutter contre des troubles hypocholinergiques du système nerveux central
SG11201406296SA (en) Centrifuge having water discharge structure and purifier system using the same
EP3347011A4 (fr) Combinaison muscarinique et son utilisation pour lutter contre des troubles hypocholinergiques du système nerveux central
EP3463417A4 (fr) Polythérapies pour la régénération/le remplacement des cellules ciliées sensorielles de l'oreille interne

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180404

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031435000

Ipc: A61K0031216000

A4 Supplementary search report drawn up and despatched

Effective date: 20190318

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/454 20060101ALI20190312BHEP

Ipc: A61K 45/06 20060101ALI20190312BHEP

Ipc: A61K 31/216 20060101AFI20190312BHEP

Ipc: A61K 31/517 20060101ALI20190312BHEP

Ipc: A61K 31/4439 20060101ALI20190312BHEP

Ipc: A61K 31/4178 20060101ALI20190312BHEP

Ipc: A61K 9/70 20060101ALI20190312BHEP

Ipc: A61P 25/24 20060101ALI20190312BHEP

Ipc: A61K 31/166 20060101ALI20190312BHEP

Ipc: A61P 25/28 20060101ALI20190312BHEP

Ipc: A61P 25/18 20060101ALI20190312BHEP

Ipc: A61P 25/00 20060101ALI20190312BHEP

Ipc: A61P 25/14 20060101ALI20190312BHEP

Ipc: A61K 31/439 20060101ALI20190312BHEP

Ipc: A61P 43/00 20060101ALI20190312BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200623

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230331

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20230310